Clinical trials: Psychiatric Illness
Alzheimer's Disease
Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
The primary objective of the study is to evaluate the safety and tolerability of a range of BIIB037 doses administered as single intravenous (IV) infusions in participants with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT01397539
- Testing
- BIIB037
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Biogen
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06072001
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Obstetric Labour, Premature, Premature Ejaculation
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
A study conducted on healthy volunteers to determine the safety, tolerability and affect on the human body by experimental drug GSK557296.
- Trial name
- NCT00549211
- Testing
- GSK557296
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mild to Moderate Dementia Due to Alzheimer's Disease, With or Without Coexisting Cerebrovascular Disease
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
This study is a randomized, double-blind, placebo-controlled, multicentre, Phase 2 study, with an optional open-label extension, to evaluate the safety, tolerability, and efficacy of RPh201 in subjects with mild to moderate AD…
- Trial name
- NCT03462121
- Testing
- RPh201
- Where
- 5 sites in Canada
- Volunteers
- 83 people
- Sponsor
- Regenera Pharma Ltd
Alzheimer Disease
A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's
The purpose of this study is to evaluate safety and target engagement of XPro1595 in Alzheimer's patients with biomarkers of inflammation.
- Trial name
- NCT03943264
- Testing
- XPro1595
- Where
- 5 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Inmune Bio, Inc.
Treatment-resistant Schizophrenia
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS)
- Trial name
- Anew (NCT03230864)
- Testing
- Lu AF35700, Risperidone, Olanzapine
- Where
- 41 sites in United States, Bulgaria and 3 more
- Volunteers
- 119 people
- Sponsor
- H. Lundbeck A/S
Anxiety Disorders
Bioequivalence Trial of Alprazolam 0.25 mg Tablets
The objective of this study was to confirm if two formulations of alprazolam (tablets) are bioequivalent. Test product was Zamoprax® 0.25 mg (GlaxoSmithKline) and reference product Tafil® 0.25 mg (Pharmacia \& Upjohn).
- Trial name
- NCT01853956
- Testing
- Alprazolam 0.25 mg
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Dementia
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00096473
- Testing
- Donepezil hydrochloride
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 229 people
- Sponsor
- Eisai Inc.
Postpartum Depression
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
In this study, researchers will learn how postpartum depression symptoms may change after people first start taking zuranolone. This is a drug available for doctors to prescribe for people with postpartum depression, also known…
- Trial name
- NCT07398469
- Testing
- Zuranolone
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Biogen
Schizophrenia
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.
- Trial name
- NCT06315283
- Testing
- TV-44749, Oral olanzapine
- Where
- 9 sites in United States, Croatia and 2 more
- Volunteers
- 153 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Alcohol Use Disorder
Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare
This is an exempt, retrospective study of a limited set of information obtained from patients' medical records at 10 to 12 substance abuse treatment programs combined with alcohol breath analyzer results during up to 3 years of…
- Trial name
- NCT02544581
- Testing
- Soberlink combined with aftercare services
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- SoberLink, LLC
Schizophrenia, Schizoaffective Disorder
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
The purpose of this study is to evaluate the long-term efficacy and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) and its influence on quality of life, in participants with…
- Trial name
- NCT00269919
- Testing
- Risperidone Long-Acting Injectable (RLAI)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
First Time in Human Study (FTIH) With Positron Emission Tomography (PET)
This study described in the present protocol consists of two sections. Part A is the first administration into man to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK1144814.
- Trial name
- NCT01381419
- Testing
- GSK1144814
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smoking Cessation, Nicotine Addiction
Innovative Digital Therapeutic for Smoking Cessation
This study is comparing the efficacy of two smoking cessation apps.
- Conditions
- Smoking Cessation, Nicotine Addiction, Drug Addiction, Drug Dependence
- Trial name
- NCT03694327
- Testing
- CT-101-M, QuitGuide
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- My Digital Study
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Tourette's Disorder
Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01416441
- Testing
- Aripiprazole
- Where
- 80 sites in United States, Bulgaria and 8 more
- Volunteers
- 170 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Conduct Disorder, Oppositional Defiant Disorder
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild…
- Conditions
- Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder
- Trial name
- NCT00250354
- Testing
- Risperidone oral solution
- Volunteers
- 110 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Major Depressive Disorder
A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.
- Trial name
- NCT00095745
- Testing
- Antidepressant + Aripiprazole
- Where
- 58 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia
- Trial name
- NCT03627195
- Testing
- DSP-1349M
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sumitomo Pharma America, Inc.
Mild Cognitive Impairment
An Examination of the Use of Electrophysiological Brain Monitoring to Direct the Treatment of Mild Cognitive Impairment
The problem of cognitive decline among the aging population has become a significant health burden, especially in light of the increase in the prevalence of dementia with age For patients with MCI (Mild cognitive impairment)…
- Trial name
- NCT03375151
- Testing
- EEG based feedback, Standard practice based feedback, No feedback
- Volunteers
- 60 people
- Sponsor
- Brainmarc Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.